Kornimate/medical-research-clean huggingface dataset:
role of phospholipid transfer proteins (pltp) on endotoxemia caused by buccal inflammation

Conditions: Patients With Periodontal Disease

Summary: this is a transversal double-centre study. patients will be recruited from outpatient consultations. they will have buccal inflammation caused by periodontal disease (frequent oral infections, mostly with gram (-) bacteria). three groups of 80 patients, corresponding to slight, moderate and severe periodontal disease, will be formed according to the results of radiological and clinical examinations.


Eligibility criteria:
inclusion criteria: pre-inclusion criteria: * persons aged from 35 to 80 years old * persons who have provided written informed consent * patients with periodontal disease whatever the severity with at least one molar or one premolar on the dental arch * possibility to examine the oral cavity (patient able to open mouth) * possibility to do an orthopantomogram (sitting position required and patient able to clench jaws) * patient able to understand french * patient who accepts to provide fasting blood sample within the five days following the initial consultation definitive inclusion criteria - patient present for the fasting blood sample within five days following the initial consultation patients will be matched for sex and, as much as possible, for age in the three groups and for the severity of the periodontal disease exclusion criteria: * persons not covered by the national health insurance agency * patients with a high risk of infectious endocarditis who require prophylaxis for any medical act involving blood * patients who have taken at least once during the 8 days preceding the definitive inclusion an anti-inflammatory dose of nsaids and/or a salicylate (blood sample) * patients who have had long-term treatment (\>6 months) with corticoids at a dose of at least 15 mg per day * patients on antibiotics less than 15 days before the blood sample * patients with oral inflammation requiring treatment with antibiotics or anti-inflammatory drugs during the pre-inclusion * scaling during the 24 hours before the blood sample * history of oral cancer or cancer of the pharynx * active cancer (patient undergoing treatment or diagnosis within the previous 5 years) * iatrogenic, spontaneous or therapeutic immunodepression (patient on immunosuppressants or antiretrovirals), * systemic or organ specific inflammatory syndrome not related to the periodontal disease * proven bacterial, viral or fungal infection either developing or being treated (urinary, prostate infection) * inflammatory cancer (solid tumour, malignant hemopathy) * pregnancy * impossibility to cooperate due to a psychiatric disease, dementia * patients unable to understand the protocol
high flux hemodialysis thrice versus once

Conditions: End-Stage Renal Disease

Summary: to investigate the influence of different dialysis frequencies on the outcome of end-stage renal disease patients undergoing chronic hemodialysis therapy.

this study will be conducted in the hd center at ntuh. patients undergoing chronic hd for at least 6 months will be evaluated for eligibility. patients with previous adverse reactions to fx series dialyzer will not be included in this study. detailed demographic physical characteristics of the participants will be recorded, including age, gender, underlying diseases, blood pressure, intradialytic complications, as well as indices of nutrition, inflammation, and dialysis adequacy. eligible patients will first undergo a 4-week run-in hd with conventional-flux dialyzer twice weekly plus high-flux dialyzer once weekly (i.e., basic formula), followed by random allocation into two separate groups. patients in group a will continue hd with the basic formula, while those in group b will receive hd using high-flux membranes thrice weekly. three months later, all participants will be put back on hd with basic formula for 1 month (wash-out period). group a patients will then be switched to receive hd with high-flux membranes thrice weekly, and group b patients will be changed to undergo hd with basic formula for another 3 months. laboratory tests will include monthly biochemistry and hemogram, plus blood and urine specimens taken on 4 occasions before and during the study (baseline, end of the first 3 months, end of wash-out, and end of the second 3 months) to investigate selective markers and indices for nutrition, inflammation, and dialysis adequacy.

Eligibility criteria:
inclusion criteria: 1. esrd patients under regular thrice weekly hd for more than 3 months in ntuh hd center. 2. age: 18\~80 years old. 3. blood flow during dialysis ≧ 250ml/min exclusion criteria: 1. previous allergy to heparin or fx series dialyzer (fx-60, fx-80, fx-100) 2. pre-dialysis systolic blood pressure ≦ 100mmhg (2week prior to enrollment) 3. bacteremia, myocardial infarction or stroke in previous 3 months. 4. known diagnosis with dialysis related amyloidosis

Keywords: high flux hemodialysis
scandinavian olecranon research in the elderly

Conditions: Olecranon Fracture

Summary: this study is designed to study the difference between operative treatment, either with tension band wiring or plate fixation, and conservative treatment of traumatic, displaced olecranon fractures in elderly population in a non-inferiority study setting.


Eligibility criteria:
inclusion criteria: * radiologically (standard ap and lateral radiographs) confirmed, displaced (≥2mm dislocation of the joint surface) fracture of the olecranon * age of patient is 75 years or over at the time of the injury exclusion criteria: * a delay more than 2 weeks after traumatic event to the day of intervention * mayo type 3 fracture * fracture continuation distal to coronoideus * other acute fracture or nerve damage of the ipsilateral upper limb * old fracture (\<6 months) or pseudoarthrosis or unhealed nerve injury of the ipsilateral upper limb * open fracture * pathological fracture * history of alcoholism, drug abuse, psychological or other emotional problems likely to jeopardize informed consent * patient's inability to understand written and spoken finnish or swedish or danish * patient's denial for participation or cognitive incapability to provide consent * patient physically unfit for surgery
the efficacy and safety of caffeic acid for esophageal cancer

Conditions: Esophagus Cancer

Summary: caffeic acid can target inhibit gasc1 (gene amplified in squamous cell carcinoma 1, also known as kdm4c and jmjd2c) expression and gasc1 is confirmed to be a new oncogene in several cancers including esophageal cancer. this study aims to investigate the efficiency and safety of coffeic acid in chinese advanced esophageal squamous cell cancer (escc).

background: more than half of global esophageal cancer cases came from china.80 percentage patients were diagnosed with advanced disease and suffered from the poor outcome.with the development of target therapy among cancers,the overall survival and life quality of patients has been continuous improved recently.however,there had little reports focusing on target therapy in esophageal cancer . caffeic acid as an ordinary drug is used for thrombocytopenia when patient received chemotherapy. newly studies shown caffeic acid can target inhibit gasc1 expression, and gasc1 is confirmed to be a new oncogene in esophageal cancer. aim: to investigate the efficiency and safety of caffeic acid in chinese advanced esophageal squamous cell cancer. methods: 240 advanced escc patients will be randomized to two arms: arm a (receiving coffeic acid treatment) or arm b (placebo group). in arm a, patients will receive coffeic acid treatment: 300mg, tid, po, continue to progress disease (pd) or die or the intolerant adverse events; in arm b, the same shape placebo tablets will be deliveried to patients. 1 years follow-up for both groups patients.patients in both arms can receive any other ways of anti cancer therapy in the same time. primary endpoints: os second endpoints: pfs

Eligibility criteria:
inclusion criteria: * chinese * esophageal squamous cell cancer * stage iv or disease recurrence * chemotherapy, or radiotherapy, or palliative care is going on exclusion criteria: * ps (performance status): ≥ 3 * severe hepatic and renal dysfunction * hypercoagulability * thrombocytosis

Keywords: esophageal cancer caffeic acid
demand - degenerative meniscal tears - arthroscopy vs. dedicated exercise

Conditions: Degenerative Meniscal Tears; Knee Osteoarthritis

Summary: patients with wear and tear in their knees (osteoarthritis) are often referred to orthopaedic surgeons following a sudden worsening of pain and mechanical symptoms (grinding, locking, giving way) in their knee due to tears of their meniscal cartilages. these tears are described as degenerative as they are not usually caused by a single injury but rather accumulation of wear and tear. it is not clear from the current available evidence what the best treatment for these patients is. their underlying arthritis is not bad enough to require joint replacement yet and they were usually managing well with minimal problems from their knee until experiencing the meniscal tear. however, some of their symptoms are likely to be due to the arthritis rather than just the tear. current treatment for these patients is usually in the form of conservative treatment with physiotherapy and supervised exercise or using arthroscopy (key-hole surgery) to trim the damaged area of the meniscus. we know from previous research that most of these patients will improve over time to some extent but it is not clear whether a greater improvement can be expected following surgery and if so, whether this applies to all patients with this problem or not. our study is intended to compare the outcome of patients with proven degenerative meniscal tears imaged on mri scans, when they are assigned to arthroscopy followed by supervised exercise or supervised exercise alone. they will be randomly assigned and the outcome will be assessed using patient-completed questionnaires (knee outcome osteoarthritis and injury score \[koos\], sf12, visual analogue score for pain) and whether the patients go on to require further surgery during the period of the trial. the patients will be assessed at baseline, at 6 weeks, 6 months, 12 months and 24 months.


Eligibility criteria:
inclusion criteria: * age over 45 years * knee pain in the presence of a medial meniscal tear on mri. exclusion criteria: * history of trauma to the knee or ipsilateral lower limb in the past 2 years * inability to engage in postoperative rehabilitation * lacking capacity to consent * evidence of infection * previous knee surgery other than arthroscopy (diagnostic or partial meniscectomy) neurological disease * inflammatory arthritis * loose bodies * ligament injuries causing symptomatic instability * women who are pregnant * have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease. * uncontrolled disease states, such as moderate/severe asthma, copd or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids, or recurrent infections.
radiation-hormone and docetaxel vs radiation-hormone in patients with high-risk localized prostate cancer

Conditions: Prostate Cancer Stage III; Prostate Cancer Stage IV

Summary: a prospective, multicenter, parallel-group, open-label, randomized, phase ii clinical study of radiation therapy, hormone therapy and docetaxel versus radiation therapy and hormone therapy in patients with high-risk localized prostate cancer (stage iii and iv) whose primary objective is determine the percentage of patients free of biochemical recurrence within 5 years of receiving a combination of radiation therapy with docetaxel associated with hormone therapy or the standard of care of radiation therapy and hormone therapy in patients with stage iii and iv localized prostate cancer with a poor prognosis.

randomized phase ii clinical study of radiation therapy, hormone therapy and chemotherapy with docetaxel versus radiation therapy and hormone therapy in patients with high-risk localized prostate cancer (stage iii and iv) primary objective: to determine the percentage of patients free of biochemical recurrence within 5 years of receiving a combination of radiation therapy with docetaxel associated with hormone therapy or the standard of care of radiation therapy and hormone therapy in patients with stage iii and iv localized prostate cancer with a poor prognosis. design: a prospective, multicenter, multidisciplinary, parallel-group, open-label study with randomized group assignment.

Eligibility criteria:
inclusion criteria: 1. histological confirmation of adenocarcinoma of the prostate. 2. age \> 18 years. 3. localized high-risk prostate cancer, defined as: * stage iii: t3 n0 m0, gleason grade 8, 9, or 10, or * stage iv: t4 n0 m0, any gleason grade or tx n1 m0, any gleason grade 4. psa \> 20 ng/ml. 5. karnofsky index ≥ 70% 6. good bone marrow reserve, with white blood cell count \> 3000/mm3, hemoglobin \>9.5 g/dl and platelets \> 150,000/mm3. 7. absence of hepatic abnormality, with bilirubin values \< 1.5 mg/dl and with sgot/sgpt values up to 2 times the upper limit of normality for each site. 8. absence of abnormality in renal function, with creatinine levels up to 2 times the upper limit of normality for each site. 9. having given informed consent in writing. exclusion criteria: 1. previous hormone treatment during more than 3 months. 2. previous surgical treatment, pelvic radiation therapy, or chemotherapy for the current illness. 3. concomitant second neoplasm or history of neoplastic disease in the last 5 years, except for cutaneous basal cell carcinoma. 4. metabolic disease or uncontrolled systemic disease. 5. previous history of grade iii-iv neuropathy (nci ctcae v3). 6. psychological, social, family, or geographical conditions that may compromise compliance with or follow-up of the study. 7. having received treatment with an investigational medicinal product during the 30 days prior to inclusion in the study. 8. inflammatory bowel disease.
pre-ercp high carbohydrate drinks improve patients recovery

Conditions: Complication

Summary: to test the benefits of extra high carbohydrate liquid diet uptake 2 hours before ercp in improving patients' early recovery.

enhanced recovery after surgery (eras) has been formed of procedure which contains preoperative education, improvement of anesthesia, reducing the number of drainage tubes, and early diet after surgery. in recent years, because of its positive advantages, eras was widely accepted in surgical fields. for upper gastrointestinal surgery, high-carbohydrate drinks can be given 2 hours before surgery in order to guarantee the stability of blood glucose and circulation during the operation. it obviously reduce the preoperative thirst, hunger, irritability and even the incidence of postoperative complications. however eras program is rarely studied in ercp. theoretically we can use eras as a strategy to reduce post-ercp uncomfortable and complications.

Eligibility criteria:
inclusion criteria: * ercp patients, * age 18-85 years old. exclusion criteria: * coagulation dysfunction (inr\> 1.3) and low peripheral blood platelet count(\<50×109 / l) or using anti-coagulation drugs, * preoperative coexistent diseases: acute pancreatitis, gi tract hemorrhage, severe liver disease, shock, liver or kidney malfunction, * diabetes（blood glucose fluctuations）or with complications, * intestinal obstruction or other contraindications with feeding and watering, * prior surgery of bismuth ⅱ and roux-en-y, * pregnant women, * unwillingness or inability to consent for the study.

Keywords: ercp eras complication fatigue high carbohydrate diet
comparison of 3-minute step test (3mstept) and 6-minute walk test (6mwt) in copd patients

Conditions: COPD; Chronic Obstructive Pulmonary Disease

Summary: the aim of this study is to compare oxygen desaturation during two tests: the 6 minute walk test and the 3 minute step test, for copd patients.

the 6 minute walk test (6mwt) is the best field test to determine oxygen desaturation during effort, in copd patients. however, the test need a 30m corridor. the 3 minute step test (3mst) is a other field test used in copd patients. but no study shows that 3mst can be used to determine oxygen desaturation. the aim of this study is to compare oxygen desaturation during these to tests : the 6mwt and the 3mst. 50 patients will be included in this study. patients realize two 6mwt and two 3mst, with rest between each test. oxygen saturation, heart rate are registered during the tests, dyspnea, leg peniblility are notified before and after each test, distance or number of steps are noted.

Eligibility criteria:
inclusion criteria: * stable copd patients hospitalized for pulmonary rehabilitation program exclusion criteria: * acute exacerbation of copd * incapacity to realize the tests * absence of written informed consent

Keywords: pulmonary rehabilitation copd evaluation oxygen desaturation exercise capacity
mri predictors of response to tumor treating fields

Conditions: Glioblastoma Multiforme

Summary: patients with glioblastoma, an aggressive brain tumor, are recommended to undergo treatment with tumor treating fields using the optune device as part of standard of care therapy. while undergoing treatment, patients are monitored regularly with brain mri scans to look for tumor progression, but there are currently no means to predict which, or when, patients will progress. the purpose of the current study is to prospectively analyze these mri scans to look for subtle imaging markers that can predict for future brain tumor progression while undergoing tumor treating field therapy.

the proposed trial involves the prospective collection of imaging data at standard clinical time points before and during treatment with ttfields. all patients who are offered treatment with ttfields will also be offered enrollment in this non-randomized, observational study. imaging data will include the standard battery of mri sequences, which includes dwi and adc reconstruction. these data will be collected at standard time points and the proposed study will not rely on any additional imaging or tests outside of the clinical standard of care.

Eligibility criteria:
inclusion criteria: * patients age 18 or older with newly diagnosed who grade iv glioblastoma or patients with recurrent glioblastoma not previously treated with ttfields. * patients may have undergone surgical resection or biopsy. * residual tumor, absence of treatment with temozolomide or radiation therapy will not be an exclusion criteria for the study. exclusion criteria: * patients previously treated with ttfields will not be included in the study. * patients will also be excluded if they are undergoing active treatment with systemic agents, including bevacizumab, during treatment with ttfields.
11c-pib pet study in mesa at columbia university

Conditions: Cognitive Impairment; Vascular Diseases; Alzheimer Disease; Atherosclerosis

Summary: the investigators will conduct a study of brain positron emission tomography (pet) using 11c-pib for the imaging of brain amyloid in 250 participants in the multiethnic study of atherosclerosis (mesa) at columbia university irving medical center in new york city. participants will be imaged only once with pittsburgh compound b (pib) pet.

this is a single center pet study of 11c-pib. eligible participants are current participants in the mesa study in new york city, without contraindications to mri or pet procedures. those eligible will have one brain pet scan with 11c-pib within 12 months of a brain mri. vital signs will be checked prior to injection of 11c-pib, 10 minutes after the injection, and again at the completion of the pet scan. the primary outcome measure for amyloid will be whole brain 11c-pib suvr. the relation between exposure groups and amyloid in the brain will be analyzed using linear regression.

Eligibility criteria:
inclusion criteria: * current participants in mesa study at columbia university * 60 years or older * fluent in english and/or spanish. * able to participate in all scheduled evaluations and to complete all required tests and procedures. exclusion criteria: * active treatment for cancer * any serious medical condition which would prevent long-term participation * pregnancy * weight \>300 pounds * participants previously diagnosed or adjudicated to have dementia * participants unwilling to undergo cognitive testing * plans to leave the community within five years * language barrier (speaks other than english, spanish, chinese) * inability to give informed consent or to obtain consent from a legally authorized representative (lar)

Keywords: alzheimer disease cognitive impairment 11c-pib atherosclerosis
effects of a health belief model-based fall prevention education program on health literacy and physical function in patients with chronic stroke

Conditions: Fall Prevention; Chronic Stroke Patients; Health Literacy; Education of Patients; Health Belief Model

Summary: the goal of this clinical trial is to to evaluate the effects of a health belief model-based fall prevention education program on health literacy and physical function, fall rate, fall risk, fear of fall, and quality of life in patients with chronic stroke. the main question it aim to answer is \* does a health belief model-based fall prevention education program have a positive effect on health literacy, physical function, fall risk, fear of falling, and quality of life in patients with chronic stroke? researchers will compare the intervention group, who will receive the health belief model-based fall prevention education program, to the control group, who will receive their usual intervention in the physical therapy clinic, to see if the health belief model-based fall prevention education program has an effect on health literacy and physical function, fall rate, fall risk, fear of falling, and quality of life in patients with chronic stroke. the clinical trial will be conducted in four phases; each participant will take around 8 weeks and will receive two in-person individual educational sessions based on the health belief model (hbm).


Eligibility criteria:
inclusion criteria: * aged 60 years and older * diagnosed with stroke (more than 6 months), * no cognitive impairment (arabic version of mini-mental state examination \[mmse-a\] score of 24 or more) * no visual or hearing impairment * able to walk independently or with assistive devices for 10 meters exclusion criteria: * severe communication deficiencies. * having neurological conditions other than stroke or other serious medical conditions that precluded participation in the study.